Merck $5.7bn deal targets bone and blood cancer
Merck is making yet another major move in the pharmaceutical world. The New Jersey-based drugmaker has agreed to acquire Terns Pharmaceuticals, a California-based biotech developing a promising treatment for a rare and life-threatening form of blood and bone cancer and the deal is worth $5.7 billion. The announcement, made Wednesday, signals just how aggressively Merck […]